Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers

Clinical Drug Investigation

Volumn 33, Issue 5, 2013, Pages 351-357

  MacHa, Sreeraj ^a   Mattheus, Michaela ^b   Pinnetti, Sabine ^b   Woerle, Hans J ^b   Broedl, Uli C ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HERPES LABIALIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; OROPHARYNX PAIN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; GERMANY; GLUCOSIDES; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; LEVONORGESTREL; METABOLIC CLEARANCE RATE; POLYPHARMACY; YOUNG ADULT;

EID: 84877030226     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0068-y     Document Type: Article

References (25)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
2. Centers for Disease Control and Prevention. Diabetes and women's health across the life stages: a public health perspective. Centers for disease control and prevention. 2001. Available from: http://www.cdc.gov/diabetes/pubs/women/ index.htm. Accessed 1 Nov 2012.
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.
4. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136-42.
5. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427-34.
6. Defronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.
7. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
8. Heise T, Seewaldt-Becker E, Macha S, et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl 1):A172 (629-P).
9. Seman L, Macha S, Jones P, et al. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl 1):A156 (571-P).
10. Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), in healthy volunteers. Diabetes. 2010;59:A155 (569-P).
11. Ferrannini E, Seman LJ, Seewaldt-Becker E, et al. The potent and highly selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(Suppl 1):S351 (877).
12. Rosenstock J, Jelaska A, Seman L, et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60(Suppl 1):A271 (989-P).
13. Bayer plc. Summary of product characteristics for microgynon. Bayer plc. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/1827/SPC/ Microgynon+30/. Accessed 1 Nov 2012.
14. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783-7.
15. Duramed Pharmaceuticals Ltd. Prescribing information for plan B one step (levonorgestrel). Duramed Pharmaceuticals Ltd. 2012. Available from: http://www.planbonestep.com/pdf/PlanBOneStepFullProductInformation.pdf. Accessed 1 Nov 2012.
16. Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinylestradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol. 2008;65:19-26.
17. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig. 2011;31:643-53.
18. Macha S, Rose P, Mattheus M et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter-2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2012; (Epub 2012 Oct 24).
19. Boehringer Ingelheim. Data on file. 2012.
20. Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17-alpha-ethinylestradiol. Drug Metab Dispos. 2004;32:1209-12.
21. Zingone M, Guirguis A, Airee A, et al. Probable drug interaction between warfarin and hormonal contraceptives. Ann Pharmacother. 2009;43:2096-112.
22. Palovaara S, Tybring G, Laine K. The effect of ethinylestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003;56:232-7.
23. Muirhead GJ, Harness J, Holt PR, et al. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol. 2000;49(Suppl 1):49S-56S.
24. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46:133-57.
25. Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers. Clin Pharmacol Drug Dev. 2012;1:181.